Skip to main content
. 2023 Jul 28;30(12):7882–7891. doi: 10.1245/s10434-023-13931-4

Table 1.

Characteristics of patients with solitary pathological proximal femoral (impending) fracture

Variable Malignant history [n = 24] No malignant history [n = 61]
Median age at diagnosis, years (IQR) 64 (55–76) 66 (61–75)
Sex Female 15 (62) 35 (57)
Side lesion Left 15 (62) 32 (52)
Fracture Actual 15 (62) 44 (72)
Impending 9 (38) 17 (28)
Impending fracture fractured 2 (22) 7 (41)
Median time to fracture, days (IQR) 16 (10–21) 0.5 (0–19)
Fracture type Neck of femur 5 (21) 17 (28)
Pertrochanteric 5 (21) 13 (21)
Subtrochanteric/diaphyseal 12 (50) 16 (26)
Greater trochanter 1 (4) 3 (5)
Lesser trochanter 0 (0) 4 (7)
Unknown 1 (4) 8 (13)
Malignant history Sarcoma 3 (12.5)
Carcinoma 21 (87.5)a
Biopsy 23 (96) 58 (95)
Median time to biopsy, days (IQR) 17 (10–29) 14 (9–21)
Biopsy histology Sarcoma 7 (29) 20 (35)
Hematologic 1 (4) 13 (22)
Carcinoma 11 (46) 5 (9)
Carcinoma unknown 3 (13) 17 (29)
Inconclusive 1 (4) 3 (5)
Diagnostic rate of biopsy 19 (83) 38 (66)
CT-TAP available 14 (58) 53 (91)
CT-TAP Inconclusive 11 (79) 36 (68)
CUPb 2 (8) 15 (25)
Median time to treatment, days (IQR) 42 (27–56) 29 (21–41)
Procedure Intramedullary nailing 2 (8) 1 (2)
Endoprosthesis 17 (71) 49 (80)
Plate 1 (4)
Disarticulation hip 1 (4) 5 (8)
Hindquarter amputation 3 (5)
Non-surgical 1 (4) 2 (3)
Unknown 2 (8) 1 (2)
Final diagnosis Sarcoma 7 (29) 24 (39)
Hematological 1 (4) 13 (21)
Carcinoma 15 (63) 17 (28)
CUP 1 (4) 7 (12)
Discrepancy History and final diagnosis 5 (21)c NA
Biopsy and final diagnosis 4 (7)d
Follow-up NED 11 (18)
AWD 1 (4) 6 (10)
DOD/DOOD 21/2 (96) 41/3 (72)
Survival from diagnosis, % (95% CI) 1 year 44 (23–62) 61 (47–73)
2 years 26 (11–45) 49 (35–62)
5 years 16 (4–34) 18 (7–32)

Data are expressed as n (%) unless otherwise specified

IQR interquartile range, CT-TAP computerized tomography scan of the thorax, abdomen and pelvis, CUP biopsy unknown and CT-TAP inconclusive, NA not applicable, NED no evidence of disease, AWD alive with disease, DOD death of disease, DOOD death of other disease, CI confidential interval

aHistory of carcinoma; breast (n = 8), bowel (n = 3), prostate (n = 2), head and neck (n = 2), bladder (n = 1), lung (n = 1), renal (n = 1), melanoma (n = 1), esophagus (n = 1), skin other (n = 1)

bCUP patients (n = 2) with a history of cancer resulted in carcinomas (one carcinoma of unknown origin) and CUP patients without a history of cancer resulted in 2 sarcomas, 1 hematologic malignancy and 12 carcinomas (7 carcinomas of unknown origin).

cDiscrepancy between carcinoma history and final diagnosis (sarcoma [n = 4], hematologic malignancy [n = 1]).

dDiscrepancy between biopsy and final diagnosis; inconclusive biopsies (n = 3) became a hematologic malignancy (n = 1) and two sarcomas at final diagnosis, one possible hematologic malignancy became a sarcoma at final diagnosis.